Progesterone Receptor Negative Recruiting Phase 1 Trials for Mirvetuximab Soravtansine (DB12489)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02996825Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast CancerTreatment